image

REPORT SCOPE & OVERVIEW:

The Autoimmune Disease Therapeutics Market size was valued at USD 72.05 billion in 2022 and it is expected to be worth around USD 94.87 billion by 2030 growing at a remarkable CAGR of 3.5% over the forecast period 2023-2030.

The autoimmune disease therapeutics market has been experiencing significant growth due to the rising incidence of autoimmune diseases globally. Factors such as genetic predisposition, environmental triggers, and lifestyle changes contribute to the increasing prevalence of autoimmune disorders. The market encompasses a wide range of autoimmune diseases, including rheumatoid arthritis, multiple sclerosis, psoriasis, lupus, type 1 diabetes, and others. Each disease may require specific therapeutic approaches. Biologics, including monoclonal antibodies and other advanced therapies, have become a major focus in autoimmune disease treatment.

Autoimmune Disease Therapeutics Market Revenue Analysis

MARKET DYNAMICS

DRIVERS

  • Increasing Prevalence of Autoimmune Diseases

  • Demand for Personalized Medicine

The rising incidence of autoimmune disorders globally is a major driver for the autoimmune disease therapeutics market. Factors such as changes in lifestyle, environmental influences, and genetic predisposition contribute to the growing prevalence

Growing interest in personalized medicine and precision therapies supports the development of tailored treatments for autoimmune diseases, enhancing efficacy and reducing side effects.

RESTRAIN

  • High Cost of Biologics

  • Side Effects and Safety Concerns

  • Complexity of Autoimmune Diseases

The high cost of biologic drugs can be a significant barrier, limiting access for some patients and impacting market growth. Immunomodulatory therapies, including biologics and immunosuppressants, may have side effects and safety concerns, influencing patient and physician preferences. The complexity of autoimmune diseases, involving diverse and interconnected pathways, poses challenges in developing targeted and effective therapeutics.

OPPORTUNITY

  • Collaborations and Partnerships

  • Patient-Centric Approaches

Collaborations between pharmaceutical companies, research institutions, and healthcare organizations can facilitate the development of innovative therapies and accelerate market growth.

The shift towards patient-centric approaches, including personalized medicine and patient engagement, creates opportunities for tailored autoimmune disease therapeutics.

CHALLENGES

  • Regulatory Challenges

  • Competition and Market Saturation

  • Access to Healthcare

Meeting regulatory standards and navigating the complex approval process for autoimmune disease therapeutics can be challenging for pharmaceutical companies.

Intense competition in the market and saturation in some segments can pose challenges for companies seeking differentiation and market share.

Disparities in healthcare access and affordability can impact the adoption of autoimmune disease therapeutics, particularly in lower-income regions.

IMPACT OF RUSSIA-UKRAINE WAR

Geopolitical instability can introduce regulatory uncertainties. Changes in political environments may affect regulatory frameworks, approval processes, and market access for pharmaceutical companies.Wars and geopolitical tensions can have broader economic consequences. Economic instability may impact healthcare budgets, healthcare infrastructure, and individuals' ability to afford and access autoimmune disease therapeutics.Ongoing conflicts can divert resources and attention away from research and development efforts in the pharmaceutical industry. This may impact the progress of new therapies and drug discovery for autoimmune diseases.

IMPACT OF ONGOING RECESSION

During a recession, individuals and healthcare systems may face financial constraints. Affordability of healthcare, including the cost of autoimmune disease therapeutics, could become a significant concern. Patients may struggle to afford medications, leading to changes in prescription patterns and potential delays or interruptions in treatment. Governments and healthcare institutions may experience budget constraints during economic downturns. This can affect funding for research and development, public health initiatives, and subsidies for certain medications, potentially impacting the autoimmune disease therapeutics market. Physicians and healthcare providers may reevaluate prescription patterns during a recession. They may opt for more cost-effective treatments or generics, potentially affecting the market share of certain autoimmune disease therapeutics.

KEY COMPANY SEGMENTATION

By Drug Class Type

  • Anti-inflammatory

  • Antihyperglycemics

  • NSAIDs

  • Interferons

  • Others

By Indication

  • Rheumatic Disease

  • Type 1 Diabetes

  • Multiple Sclerosis

  • Inflammatory Bowel Disease

  • Other Indications

By Sales Channel

  • Hospital Pharmacy

  • Drug Store & Retail Pharmacy

  • Online Store

Autoimmune Disease Therapeutics Market Segmentation Analysis

REGIONAL COVERAGE

North America

  • USA

  • Canada

  • Mexico

Europe

  • Eastern Europe

    • Poland

    • Romania

    • Hungary

    • Turkey

    • Rest of Eastern Europe

  • Western Europe

    • Germany

    • France

    • UK

    • Italy

    • Spain

    • Netherlands

    • Switzerland

    • Austria

    • Rest of Western Europe

Asia Pacific

  • China

  • India

  • Japan

  • South Korea

  • Vietnam

  • Singapore

  • Australia

  • Rest of Asia Pacific

Middle East & Africa

  • Middle East

    • UAE

    • Egypt

    • Saudi Arabia

    • Qatar

    • Rest of Middle East

  • Africa

    • Nigeria

    • South Africa

    • Rest of Africa

Latin America

  • Brazil

  • Argentina

  • Colombia

  • Rest of Latin America

REGIONAL ANALYSES

North America, United States and Canada these countries have well-established healthcare systems and high prevalence rates of autoimmune diseases. The market is characterized by the presence of major pharmaceutical companies, a robust pipeline of new therapies, and a focus on biologics and targeted therapies.

Western Europe countries like Germany, France, and the UK have advanced healthcare systems and a significant market for autoimmune disease therapeutics. Biosimilars adoption is notable, and regulatory bodies like the European Medicines Agency (EMA) play a crucial role in market dynamics. Eastern Europe access to advanced therapeutics may vary, and economic conditions can impact market growth. However, there is an increasing focus on improving healthcare infrastructure. Asia-Pacific, China and Japan these countries have a growing market for autoimmune disease therapeutics due to increasing prevalence rates. The regulatory landscape is evolving, and there is a rising emphasis on research and development.

Key Players

The major key players are Abbott Laboratories, AbbVie Inc., Amgen Inc., AstraZeneca Plc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd. (Genentech, Inc.,), Johnson & Johnson, Novartis AG, Pfizer Inc., UCB S.A.and others.

RECENT DEVELOPMENT

In June 2023: AstraZeneca initiated a promising collaboration by entering into an exclusive option and license agreement with Quell Therapeutics. This partnership is geared towards advancing the development of engineered T-regulator (Treg) cell therapies, demonstrating significant potential for providing curative solutions for both Type 1 Diabetes (T1D) and Inflammatory Bowel Disease (IBD).

In January 2023: Researchers at Penn Medicine have achieved notable progress in the pursuit of a personalized treatment for the rare autoimmune condition known as myasthenia gravis (MG). Employing the innovative chimeric antigen receptor (CAR) T cell therapy, commonly utilized in the treatment of specific cancer types, they have identified a potential approach to address this particular autoimmune disease.

Autoimmune Disease Therapeutics Market Report Scope:
Report Attributes Details
Market Size in 2022  US$ 72.05 Bn
Market Size by 2030  US$ 94.87 Bn
CAGR   CAGR of 3.5% From 2023 to 2030
Base Year  2022
Forecast Period  2023-2030
Historical Data  2020-2021
Report Scope & Coverage Market Size, Segments Analysis, Competitive  Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook
Key Segments • By Drug Class Type (Anti-inflammatory, Antihyperglycemics, NSAIDs, Interferons, Others)
• By Indication (Rheumatic Disease, Type 1 Diabetes, Multiple Sclerosis, Inflammatory Bowel Disease, Other Indications)
• By Sales Channel (Hospital Pharmacy, Drug Store & Retail Pharmacy, Online Store)
Regional Analysis/Coverage North America (US, Canada, Mexico), Europe (Eastern Europe [Poland, Romania, Hungary, Turkey, Rest of Eastern Europe] Western Europe] Germany, France, UK, Italy, Spain, Netherlands, Switzerland, Austria, Rest of Western Europe]), Asia Pacific (China, India, Japan, South Korea, Vietnam, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (Middle East [UAE, Egypt, Saudi Arabia, Qatar, Rest of Middle East], Africa [Nigeria, South Africa, Rest of Africa], Latin America (Brazil, Argentina, Colombia Rest of Latin America)
Company Profiles

Abbott Laboratories, AbbVie Inc., Amgen Inc., AstraZeneca Plc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd. (Genentech, Inc.), Johnson & Johnson, Novartis AG, Pfizer Inc., UCB S.A.

Key Drivers • Increasing Prevalence of Autoimmune Diseases
• Demand for Personalized Medicine
Market Opportunities • Collaborations and Partnerships
• Patient-Centric Approaches

 

Frequently Asked Questions

Ans: The Autoimmune disease therapeutics market is growing at a CAGR of 3.5% From 2023 to 2030.

Ans: The Autoimmune disease therapeutics market is projected to reach USD 94.87 billion by 2030.

Ans: The major key players are Abbott Laboratories, AbbVie Inc., Amgen Inc., AstraZeneca Plc., Bristol-Myers Squibb Company, and others.

Ans: Increasing prevalence of autoimmune diseases in North America is key driving factor.

Ans: North America holds a substantial market share.

Table of Contents

1. Introduction

1.1 Market Definition

1.2 Scope

1.3 Research Assumptions

2. Research Methodology

3. Market Dynamics

3.1 Drivers

3.2 Restraints

3.3 Opportunities

3.4 Challenges

4. Impact Analysis

4.1 Impact of the Ukraine- Russia war

4.2 Impact of ongoing Recession

4.2.1 Introduction

4.2.2 Impact on major economies

4.2.2.1 US

4.2.2.2 Canada

4.2.2.3 Germany

4.2.2.4 France

4.2.2.5 United Kingdom

4.2.2.6 China

4.2.2.7 Japan

4.2.2.8 South Korea

4..2.9 Rest of the World

5. Value Chain Analysis

6. Porter’s 5 forces model

7. PEST Analysis

8.Autoimmune disease therapeutics market, By Drug Class Type

8.1 Anti-inflammatory

8.2 Antihyperglycemics

8.3 NSAIDs

8.4 Interferons

8.5 Others

9.Autoimmune disease therapeutics market, By Indication

9.1 Rheumatic Disease

9.2 Type 1 Diabetes

9.3 Multiple Sclerosis

9.4 Inflammatory Bowel Disease

9.5 Other Indications

10.Autoimmune disease therapeutics market, By Sales Channel

10.1 Hospital Pharmacy

10.2 Drug Store & Retail Pharmacy

10.3 Online Store

11. Regional Analysis

11.1 Introduction

11.2 North America

11.2.1 North America Autoimmune disease therapeutics market by country

11.2.2North America Autoimmune disease therapeutics market By Drug Class Type

11.2.3 North America Autoimmune disease therapeutics market By Indication

11.2.4 North America Autoimmune disease therapeutics market By Sales Channel

11.2.5 USA     

11.2.5.1 USA Autoimmune disease therapeutics market By Drug Class Type

11.2.5.2 USA Autoimmune disease therapeutics market By Indication

11.2.5.3 USA Autoimmune disease therapeutics market By Sales Channel

11.2.6 Canada

11.2.6.1 Canada Autoimmune disease therapeutics market By Drug Class Type

11.2.6.2 Canada Autoimmune disease therapeutics market By Indication

11.2.6.3 Canada Autoimmune disease therapeutics market By Sales Channel

11.2.7 Mexico

11.2.7.1 Mexico Autoimmune disease therapeutics market By Drug Class Type

11.2.7.2 Mexico Autoimmune disease therapeutics market By Indication

11.2.7.3 Mexico Autoimmune disease therapeutics market By Sales Channel

11.3 Europe

11.3.1 Eastern Europe

11.3.1.1 Eastern Europe Autoimmune disease therapeutics market by country

11.3.1.2 Eastern Europe Autoimmune disease therapeutics market By Drug Class Type        

11.3.1.3 Eastern Europe Autoimmune disease therapeutics market By Indication

11.3.1.4 Eastern Europe Autoimmune disease therapeutics market By Sales Channel

11.3.1.5 Poland

11.3.1.5.1 Poland Autoimmune disease therapeutics market By Drug Class Type

11.3.1.5.2 Poland Autoimmune disease therapeutics market By Indication

11.3.1.5.3 Poland Autoimmune disease therapeutics market By Sales Channel

11.3.1.6 Romania

11.3.1.6.1 Romania Autoimmune disease therapeutics market By Drug Class Type    

11.3.1.6.2 Romania Autoimmune disease therapeutics market By Indication

11.3.1.6.4 Romania Autoimmune disease therapeutics market By Sales Channel

11.3.1.7 Turkey

11.3.1.7.1 Turkey Autoimmune disease therapeutics market By Drug Class Type

11.3.1.7.2 Turkey Autoimmune disease therapeutics market By Indication

11.3.1.7.3 Turkey Autoimmune disease therapeutics market By Sales Channel

11.3.1.8 Rest of Eastern Europe

11.3.1.8.1 Rest of Eastern Europe Autoimmune disease therapeutics market By Drug Class Type

11.3.1.8.2 Rest of Eastern Europe Autoimmune disease therapeutics market By Indication

11.3.1.8.3 Rest of Eastern Europe Autoimmune disease therapeutics market By Sales Channel

11.3.2 Western Europe 

11.3.2.1 Western Europe Autoimmune disease therapeutics market By Drug Class Type       

11.3.2.2 Western Europe Autoimmune disease therapeutics market By Indication

11.3.2.3 Western Europe Autoimmune disease therapeutics market By Sales Channel 

11.3.2.4 Germany

11.3.2.4.1 Germany Autoimmune disease therapeutics market By Drug Class Type    

11.3.2.4.2 Germany Autoimmune disease therapeutics market By Indication

11.3.2.4.3 Germany Autoimmune disease therapeutics market By Sales Channel

11.3.2.5 France 

11.3.2.5.1 France Autoimmune disease therapeutics market By Drug Class Type

11.3.2.5.2 France Autoimmune disease therapeutics market By Indication

11.3.2.5.3 France Autoimmune disease therapeutics market By Sales Channel

11.3.2.6 UK

11.3.2.6.1 UK Autoimmune disease therapeutics market By Drug Class Type

11.3.2.6.2 UK Autoimmune disease therapeutics market By Indication

11.3.2.6.3 UK Autoimmune disease therapeutics market By Sales Channel

11.3.2.7 Italy

11.3.2.7.1 Italy Autoimmune disease therapeutics market By Drug Class Type

11.3.2.7.2 Italy Autoimmune disease therapeutics market By Indication

11.3.2.7.3 Italy Autoimmune disease therapeutics market By Sales Channel

11.3.2.8 Spain

11.3.2.8.1 Spain Autoimmune disease therapeutics market By Drug Class Type

11.3.2.8.2 Spain Autoimmune disease therapeutics market By Indication

11.3.2.8.3 Spain Autoimmune disease therapeutics market By Sales Channel

11.3.2.9 Netherlands

11.3.2.9.1 Netherlands Autoimmune disease therapeutics market By Drug Class Type          

11.3.2.9.2 Netherlands Autoimmune disease therapeutics market By Indication

11.3.2.9.3 Netherlands Autoimmune disease therapeutics market By Sales Channel

11.3.2.10 Switzerland

11.3.2.10.1 Switzerland Autoimmune disease therapeutics market By Drug Class Type         

11.3.2.10.2 Switzerland Autoimmune disease therapeutics market By Indication

11.3.2.10.3 Switzerland Autoimmune disease therapeutics market By Sales Channel

11.3.2.11.1 Austria 

11.3.2.11.2 Austria Autoimmune disease therapeutics market By Drug Class Type

11.3.2.11.3 Austria Autoimmune disease therapeutics market By Indication   

11.3.2.11.4 Austria Autoimmune disease therapeutics market By Sales Channel

11.3.2.12 Rest of Western Europe

11.3.2.12.1 Rest of Western Europe Autoimmune disease therapeutics market By Drug Class Type

11.3.2.12.2 Rest of Western Europe Autoimmune disease therapeutics market By Indication

11.3.2.12.3 Rest of Western Europe Autoimmune disease therapeutics market By Sales Channel

11.4 Asia-Pacific

11.4.1 Asia-Pacific Autoimmune disease therapeutics market by country

11.4.2 Asia-Pacific Autoimmune disease therapeutics market By Drug Class Type      

11.4.3 Asia-Pacific Autoimmune disease therapeutics market By Indication

11.4.4 Asia-Pacific Autoimmune disease therapeutics market By Sales Channel

11.4.5 China

11.4.5.1 China Autoimmune disease therapeutics market By Drug Class Type 

11.4.5.2 China Autoimmune disease therapeutics market By Sales Channel     

11.4.5.3 China Autoimmune disease therapeutics market By Indication

11.4.6 India

11.4.6.1 India Autoimmune disease therapeutics market By Drug Class Type

11.4.6.2 India Autoimmune disease therapeutics market By Indication

11.4.6.3 India Autoimmune disease therapeutics market By Sales Channel

11.4.7 Japan

11.4.7.1 Japan Autoimmune disease therapeutics market By Drug Class Type

11.4.7.2 Japan Autoimmune disease therapeutics market By Indication

11.4.7.3 Japan Autoimmune disease therapeutics market By Sales Channel

11.4.8 South Korea

11.4.8.1 South Korea Autoimmune disease therapeutics market By Drug Class Type

11.4.8.2 South Korea Autoimmune disease therapeutics market By Indication

11.4.8.3 South Korea Autoimmune disease therapeutics market By Sales Channel

11.4.9 Vietnam

11.4.9.1 Vietnam Autoimmune disease therapeutics market By Drug Class Type

11.4.9.2 Vietnam Autoimmune disease therapeutics market By Indication

11.4.9.3 Vietnam Autoimmune disease therapeutics market By Sales Channel

11.4.10 Singapore

11.4.10.1 Singapore Autoimmune disease therapeutics market By Drug Class Type

11.4.10.2 Singapore Autoimmune disease therapeutics market By Indication

11.4.10.3 Singapore Autoimmune disease therapeutics market By Sales Channel                                  

11.4.11 Australia

11.4.11.1 Australia Autoimmune disease therapeutics market By Drug Class Type

11.4.11.2 Australia Autoimmune disease therapeutics market By Indication

11.4.11.3 Australia Autoimmune disease therapeutics market By Sales Channel

11.4.12 Rest of Asia-Pacific

11.4.12.1 Rest of Asia-Pacific Autoimmune disease therapeutics market By Drug Class Type

11.4.12.2 Rest of Asia-Pacific Autoimmune disease therapeutics market By Indication

11.4.12.3 Rest of Asia-Pacific Autoimmune disease therapeutics market By Sales Channel

11.5 Middle East & Africa

11.5.1 Middle East

11.5.1.1 Middle East Autoimmune disease therapeutics market by country

11.5.1.2 Middle East Autoimmune disease therapeutics market By Drug Class Type

11.5.1.3 Middle East Autoimmune disease therapeutics market By Indication

11.5.1.4 Middle East Autoimmune disease therapeutics market By Sales Channel

11.5.1.5 UAE

11.5.1.5.1 UAE Autoimmune disease therapeutics market By Drug Class Type

11.5.1.5.2 UAE Autoimmune disease therapeutics market By Indication

11.5.1.5.3 UAE Autoimmune disease therapeutics market By Sales Channel

11.5.1.6 Egypt

11.5.1.6.1 Egypt Autoimmune disease therapeutics market By Drug Class Type

11.5.1.6.2 Egypt Autoimmune disease therapeutics market By Indication

11.5.1.6.3 Egypt Autoimmune disease therapeutics market By Sales Channel

11.5.1.7 Saudi Arabia 

11.5.1.7.1 Saudi Arabia Autoimmune disease therapeutics market By Drug Class Type

11.5.1.7.2 Saudi Arabia Autoimmune disease therapeutics market By Indication

11.5.1.7.3 Saudi Arabia Autoimmune disease therapeutics market By Sales Channel

11.5.1.8 Qatar

11.5.1.8.1 Qatar Autoimmune disease therapeutics market By Drug Class Type

11.5.1.8.2 Qatar Autoimmune disease therapeutics market By Indication

11.5.1.8.3 Qatar Autoimmune disease therapeutics market By Sales Channel

11.5.1.9 Rest of Middle East

11.5.1.9.1 Rest of Middle East Autoimmune disease therapeutics market By Drug Class Type

11.5.1.9.2 Rest of Middle East Autoimmune disease therapeutics market By Indication

11.5.1.9.3 Rest of Middle East Autoimmune disease therapeutics market By Sales Channel

11.5.2 Africa

11.5.2.1 Africa Transfusion Diagnostics Market by country

11.5.2.2 Africa Autoimmune disease therapeutics market By Drug Class Type

11.5.2.3 Africa Autoimmune disease therapeutics market By Indication

11.5.2.4 Africa Autoimmune disease therapeutics market By Sales Channel

11.5.2.5 Nigeria

11.5.2.5.1 Nigeria Autoimmune disease therapeutics market By Drug Class Type

11.5.2.5.2 Nigeria Autoimmune disease therapeutics market By Indication

11.5.2.5.3 Nigeria Autoimmune disease therapeutics market By Sales Channel

11.5.2.6 South Africa

11.5.2.6.1 South Africa Autoimmune disease therapeutics market By Drug Class Type

11.5.2.6.2 South Africa Autoimmune disease therapeutics market By Indication

11.5.2.6.3 South Africa Autoimmune disease therapeutics market By Sales Channel

11.5.2.7 Rest of Africa

11.5.2.7.1 Rest of Africa Autoimmune disease therapeutics market By Drug Class Type

11.5.2.7.2 Rest of Africa Autoimmune disease therapeutics market By Indication

11.5.2.7.3 Rest of Africa Autoimmune disease therapeutics market By Sales Channel

11.6 Latin America

11.6.1 Latin America Autoimmune disease therapeutics market by country

11.6.2 Latin America Autoimmune disease therapeutics market By Drug Class Type

11.6.3 Latin America Autoimmune disease therapeutics market By Indication

11.6.4 Latin America Autoimmune disease therapeutics market By Sales Channel

11.6.5 Brazil

11.6.5.1 Brazil America Wound Closure By Drug Class Type

11.6.5.2 Brazil America Wound Closure By Indication

11.6.5.3 Brazil America Wound Closure By Sales Channel

11.6.6 Argentina

11.6.6.1 Argentina America Wound Closure By Drug Class Type

11.6.6.2 Argentina America Wound Closure By Indication

11.6.6.3 Argentina America Wound Closure By Sales Channel

11.6.7 Colombia

11.6.7.1 Colombia America Wound Closure By Drug Class Type

11.6.7.2 Colombia America Wound Closure By Indication

11.6.7.3 Colombia America Wound Closure By Sales Channel

11.6.8 Rest of Latin America

11.6.8.1 Rest of Latin America Wound Closure By Drug Class Type

11.6.8.2 Rest of Latin America Wound Closure By Indication

11.6.8.3 Rest of Latin America Wound Closure By Sales Channel

12. Company profile

12.1 Abbott Laboratories

12.1.1 Company Overview

12.1.2 Financials

12.1.3 Product/Services/Offerings

12.1.4 SWOT Analysis

12.1.5 The SNS View

12.2 AbbVie Inc.

12.2.1 Company Overview

12.2.2 Financials

12.2.3 Product/Services/Offerings

12.2.4 SWOT Analysis

12.2.5 The SNS View

12.3  AstraZeneca Plc.

12.3.1 Company Overview

12.3.2 Financials

12.3.3 Product/Services/Offerings

12.3.4 SWOT Analysis

12.3.5 The SNS View

12.4 Bristol-Myers Squibb Company

12.4.1 Company Overview

12.4.2 Financials

12.4.3 Product/Services/Offerings

12.4.4 SWOT Analysis

12.4.5 The SNS View

12.5  F. Hoffmann-La Roche Ltd.

12.5.1 Company Overview

12.5.2 Financials

12.5.3 Product/Services/Offerings

12.5.4 SWOT Analysis

12.5.5 The SNS View

12.6  Johnson & Johnson

12.6.1 Company Overview

12.6.2 Financials

12.6.3 Product/Services/Offerings

12.6.4 SWOT Analysis

12.6.5 The SNS View

12.7 Novartis AG

12.7.1 Company Overview

12.7.2 Financials

12.7.3 Product/Services/Offerings

12.7.4 SWOT Analysis

12.7.5 The SNS View

12.8  Pfizer Inc.

12.8.2 Financials

12.8.3 Product/Services/Offerings

12.8.4 SWOT Analysis

12.8.5 The SNS View

12.9 UCB S.A.

12.9.1 Company Overview

12.9.2 Financials

12.9.3 Product/Services/Offerings

12.9.4 SWOT Analysis

12.9.5 The SNS View

12.10 Amgen Inc.

12.10.1 Company Overview

12.10.2 Financials

12.10.3 Product/Services/Offerings

12.10.4 SWOT Analysis

12.10.5 The SNS View

13. Competitive Landscape

13.1 Competitive Bench marking

13.2 Market Share Analysis

13.3 Recent Developments

13.3.1 Industry News

13.3.2 Company News

13.3.3 Mergers & Acquisitions

14. Use Case and Best Practices

15. Conclusion

An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.

Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.

 

The 5 steps process:

Step 1: Secondary Research:

Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.

Secondary Research

Step 2: Primary Research

When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data.  This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.

We at SNS Insider have divided Primary Research into 2 parts.

Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.

This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.

Primary Research

Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.

Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.

Step 3: Data Bank Validation

Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.

Data Bank Validation

Step 4: QA/QC Process

After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.

Step 5: Final QC/QA Process:

This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.

Start a Conversation

Hi! Click one of our member below to chat on Phone